期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 229, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.114051
关键词
BLK; Tyrosine kinase; Covalent inhibitor; B cell lymphoma
资金
- Science, Technology and Innovation Commission of Shenzhen Municipality [JCYJ20170818085512379, JCYJ20200109120414564, GXWD2020 1231165807007]
- National Natural Science Foundation of China [81872749]
In this study, a novel series of selective and irreversible inhibitors of BLK were discovered, showing potent antiproliferative activities against several B-cell lymphoma cell lines. These compounds represent the first selective inhibitors developed for BLK, which could expedite the exploration of BLK functions.
B-lymphoid tyrosine kinase (BLK), a member of the SRC family nonreceptor tyrosine kinase, is involved in the B-cell receptor (BCR) signaling pathway and B cell development and function. Dysregulation of BLK is associated with autoimmune diseases and cancer. However, there is an absence of good tool compounds for BLK, and the molecular mechanisms by which BLK mediates physiological and pathological processes are poorly understood. Herein, we present the discovery of a novel series of selective and irreversible inhibitors of BLK with nanomolar potency against BLK in biochemical and cellular assays. Compound 25 demonstrated potent antiproliferative activities against several B cell lymphoma cell lines. These compounds constitute the first series of selective inhibitors developed for BLK and could help expedite the exploration of BLK functions.(c) 2021 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据